

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

PROGENICS PHARMACEUTICALS INC
Form 8-K
October 13, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 7, 2004

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23143	13-3379479
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York	10591
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (914) 789-2800

(Former name or former address, if changed since last report.)

Section 8 - Other Events

Item 8.01 Other Events

On October 7, 2004, Progenics Pharmaceuticals, Inc. issued a press release announcing that the target enrollment been reached in the Phase 2 study of its investigational drug, Methylnaltrexone for the treatment of post operative ileus (POI). A copy of the press release is attached as Exhibit 99.1 and the information contained therein is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statement and Exhibits

(c) the following exhibits are filed with this report

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

Exhibit Number

Description

99.1

Press release dated October 7, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ROBERT A. MCKINNEY

Robert A. McKinney
Vice President, Finance & Operations

Date: October 7, 2004